<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="generations containing alpha, beta, delta, and gamma. Among these generations," exact="alpha" post="and beta are human coronaviruses (HCoVs)1,2 In late December"/>
 <result pre="Novel Coronavirus-induced Pneumonia, have been suggested antiviral agents containing: Interferon" exact="alpha" post="(IFN-Î±), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol as potential"/>
 <result pre="have been suggested antiviral agents containing: Interferon alpha (IFN-Î±), lopinavir/ritonavir," exact="chloroquine" post="phosphate, ribavirin, and arbidol as potential options in COVID-19"/>
 <result pre="Table 1 Drug Adult Dosage Pediatric Dosage Route of Administration" exact="Chloroquine" post="phosphate 500 mg (300 mg for chloroquine base) twice"/>
 <result pre="Route of Administration Chloroquine phosphate 500 mg (300 mg for" exact="chloroquine" post="base) twice daily25 Not recommended Oral Hydroxychloroquine 200 mg"/>
 <result pre="(300 mg for chloroquine base) twice daily25 Not recommended Oral" exact="Hydroxychloroquine" post="200 mg twice daily26 Not recommended Oral Lopinavir/Ritonavir 400mg/100"/>
 <result pre="â€¢40: 400 mg/100 mg/time, twice daily for 1â€&quot;2 weeks27 Oral" exact="Ribavirin" post="500 mg twice dailyin combination with IFN-Î± or lopinavir/ritonavir25"/>
 <result pre="mg twice daily 26 Not recommended Oral 1Body weight 2Interferon" exact="alpha" post="Table 2 Classification of drugs that have been considered"/>
 <result pre="COVID-19 Investigational and/or hypothesis 1. Desferrioxamine34,352. Teicoplanin313. Etoposide36 - 1Interferon" exact="alpha" post="2Interferon alpha 2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation"/>
 <result pre="and/or hypothesis 1. Desferrioxamine34,352. Teicoplanin313. Etoposide36 - 1Interferon alpha 2Interferon" exact="alpha" post="2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation Chloroquine/Hydroxychloroquine Chloroquine"/>
 <result pre="2Interferon alpha 2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation Chloroquine/Hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are immunomodulant antimalarial agents with broad-spectrum antiviral"/>
 <result pre="2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation Chloroquine/Hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are immunomodulant antimalarial agents with broad-spectrum antiviral effects which"/>
 <result pre="which have been considered for potential benefits in COVID-19 treatment." exact="Hydroxychloroquine" post="is a common drug in many autoimmune disorders such"/>
 <result pre="COVID-19.37,38 Previous in vitro studies confirmed the antiviral activity of" exact="chloroquine" post="against COVID-19. Also, a recent publication from a Chinese"/>
 <result pre="from a Chinese clinical trial reported that the use of" exact="chloroquine" post="phosphate in patients with COVID-19 is superior and have"/>
 <result pre="its beneficial effect in COVID-19 treatment.37 The recommended dose of" exact="chloroquine" post="in patients with mild, moderate, or severe COVID-19 pneumonia"/>
 <result pre="moderate, or severe COVID-19 pneumonia is 500 mg twice daily." exact="Chloroquine" post="is a safe, available, and clinically applicable drug for"/>
 <result pre="safe, available, and clinically applicable drug for COVID-19 patients. Since" exact="hydroxychloroquine" post="has the same mechanism of action to chloroquine, so"/>
 <result pre="effects in the treatment of COVID-19 pneumonia.39 750 mg of" exact="chloroquine" post="is equal to 1200 mg of hydroxychloroquine.38 The recommended"/>
 <result pre="equal to 1200 mg of hydroxychloroquine.38 The recommended dose of" exact="hydroxychloroquine" post="in COVID-19 is 200 mg twice daily. Chloroquine and"/>
 <result pre="dose of hydroxychloroquine in COVID-19 is 200 mg twice daily." exact="Chloroquine" post="and hydroxychloroquine have been considered as potential candidates against"/>
 <result pre="hydroxychloroquine in COVID-19 is 200 mg twice daily. Chloroquine and" exact="hydroxychloroquine" post="have been considered as potential candidates against COVID-19 pneumonia.40,41"/>
 <result pre="candidates against COVID-19 pneumonia.40,41 An open-label non-randomized clinical trial on" exact="hydroxychloroquine" post="and azithromycin co-administration in COVID-19 patients was performed in"/>
 <result pre="COVID-19 pneumonia.40,41 An open-label non-randomized clinical trial on hydroxychloroquine and" exact="azithromycin" post="co-administration in COVID-19 patients was performed in France. Results"/>
 <result pre="in COVID-19 patients was performed in France. Results revealed that" exact="hydroxychloroquine" post="could significantly reduce the viral load and azithromycin could"/>
 <result pre="revealed that hydroxychloroquine could significantly reduce the viral load and" exact="azithromycin" post="could reinforce its clinical effect, but the main limitation"/>
 <result pre="management.43 Results of a systematic review on the efficacy of" exact="hydroxychloroquine" post="or chloroquine on the prevention or treatment of COVID-19"/>
 <result pre="of a systematic review on the efficacy of hydroxychloroquine or" exact="chloroquine" post="on the prevention or treatment of COVID-19 revealed that"/>
 <result pre="and meta-analysis on 53 randomized clinical trials on administration of" exact="hydroxychloroquine" post="in COVID-19 management revealed that hydroxychloroquine administration (case group)"/>
 <result pre="trials on administration of hydroxychloroquine in COVID-19 management revealed that" exact="hydroxychloroquine" post="administration (case group) was significantly associated with higher incidence"/>
 <result pre="of action in coronavirus treatment Recently published studies revealed that" exact="chloroquine" post="could highly reduce COVID-19 replication with an acceptable effective"/>
 <result pre="of 500 mg twice daily. The most important advantage of" exact="chloroquine" post="in COVID-19 treatment is good penetration to tissues especially"/>
 <result pre="tissues especially lungs which are highly affected in COVID-19 pneumonia." exact="Chloroquine" post="could stop viral infection by enhancing the pH of"/>
 <result pre="modification of COVID-19 viruses (inhibition of entry and post-entry stages).40" exact="Chloroquine" post="is a weak base that could be entrapped in"/>
 <result pre="and have low-pH, so interfering with their acidification process. Therefore" exact="chloroquine" post="could inhibit pH-dependent viral fusion and replication. Also, it"/>
 <result pre="endoplasmic reticulum-Golgi intermediate like structures.47 Another possible antiviral mechanism of" exact="chloroquine" post="is its immunomodulatory effect through cell signaling pathways and"/>
 <result pre="from COVID-19-induced ARDS by attenuating the pro-inflammatory cytokines and receptors.47" exact="Hydroxychloroquine" post="can enhance intracellular pH and avoid lysosomal activity in"/>
 <result pre="immune system over-activation, caused by COVID-19. According to this mechanism," exact="hydroxychloroquine" post="could alleviate symptoms of mild to severe COVID-19 pneumonia.38"/>
 <result pre="symptoms of mild to severe COVID-19 pneumonia.38 Chloroquine/Hydroxychloroquine adverse reactions" exact="Chloroquine" post="has different adverse reactions such as cardiovascular adverse reactions"/>
 <result pre="results of a systematic review on dermatologic adverse effects of" exact="hydroxychloroquine" post="emphasized that the most common dermatologic reactions due to"/>
 <result pre="hydroxychloroquine emphasized that the most common dermatologic reactions due to" exact="hydroxychloroquine" post="administration were rash, SJS,toxic epidermal necrolysis (TEN), pruritus, hyperpigmentation,"/>
 <result pre="mostly occurred after cumulative dosages of hydroxychloroquine.51 In overall, since" exact="hydroxychloroquine" post="has lower tissue accumulation potential in comparison with chloroquine,"/>
 <result pre="reactions and would be better choice.38 Chloroquine/Hydroxychloroquine contraindications Contraindications in" exact="chloroquine" post="use contains hypersensitivity to chloroquine (4-aminoquinolone compounds) and the"/>
 <result pre="choice.38 Chloroquine/Hydroxychloroquine contraindications Contraindications in chloroquine use contains hypersensitivity to" exact="chloroquine" post="(4-aminoquinolone compounds) and the presence of retinal or visual"/>
 <result pre="the presence of retinal or visual field changes.52 Chloroquine/Hydroxychloroquine pharmacokinetics" exact="Chloroquine" post="and hydroxychloroquine can distribute widely in the whole body"/>
 <result pre="of retinal or visual field changes.52 Chloroquine/Hydroxychloroquine pharmacokinetics Chloroquine and" exact="hydroxychloroquine" post="can distribute widely in the whole body after oral"/>
 <result pre="can distribute widely in the whole body after oral administration." exact="Hydroxychloroquine" post="has incomplete and variable (about 70%) absorption, while chloroquine"/>
 <result pre="administration. Hydroxychloroquine has incomplete and variable (about 70%) absorption, while" exact="chloroquine" post="has rapid and almost complete absorption. Both have moderate"/>
 <result pre="Both have moderate plasma protein binding. Both have hepatic metabolism." exact="Chloroquine" post="has an elimination half-life of 4 to 5 days"/>
 <result pre="has an elimination half-life of 4 to 5 days while" exact="hydroxychloroquine" post="has an elimination half-life of about 40 days. The"/>
 <result pre="acidification.52 Patients with predisposing diseases and special conditions Cardiovascular diseases" exact="Chloroquine" post="and hydroxychloroquine have a narrow therapeutic index and poisoning"/>
 <result pre="with predisposing diseases and special conditions Cardiovascular diseases Chloroquine and" exact="hydroxychloroquine" post="have a narrow therapeutic index and poisoning could be"/>
 <result pre="cardiovascular disease.37 Long-term exposure to these drugs could induce cardiomyopathy.38" exact="Chloroquine" post="in patients consuming heparin, prone the patients to risk"/>
 <result pre="consuming heparin, prone the patients to risk of bleeding. Also," exact="chloroquine" post="in patients with digitalization (using digoxin) could cause cardiac"/>
 <result pre="block.27 Liver diseases There is no dosage adjustment available for" exact="chloroquine" post="or hydroxychloroquine in patients with hepatic failure but it"/>
 <result pre="diseases There is no dosage adjustment available for chloroquine or" exact="hydroxychloroquine" post="in patients with hepatic failure but it should be"/>
 <result pre="caution.52 Kidney diseases There is no dosage adjustments available for" exact="chloroquine" post="in patients with renal failure from the manufacture's labeling"/>
 <result pre="adjustment is required. There is no dosage adjustments available for" exact="hydroxychloroquine" post="in renal failure but it should be used with"/>
 <result pre="showed a low risk of congenital abnormalities in patients receiving" exact="chloroquine" post="during pregnancy because of the lack of a pattern"/>
 <result pre="that the benefits of its use are higher than risks.53" exact="Hydroxychloroquine" post="use during pregnancy could not be accompanied by risks"/>
 <result pre="But patient monitoring during pregnancy is required.53 In general, since" exact="chloroquine" post="may induce severe side effects during fetal development, so"/>
 <result pre="chloroquine may induce severe side effects during fetal development, so" exact="hydroxychloroquine" post="would be a better option in pregnant women with"/>
 <result pre="during pregnancy.38 Lactation According to the American Academy of Pediatrics," exact="chloroquine" post="is compatible with breastfeeding. Although it could be excreted"/>
 <result pre="for nursing infants.53 According to the American Academy of Pediatrics," exact="hydroxychloroquine" post="is compatible with breastfeeding. Small amounts of hydroxychloroquine could"/>
 <result pre="of Pediatrics, hydroxychloroquine is compatible with breastfeeding. Small amounts of" exact="hydroxychloroquine" post="could be excreted to the milk, but because of"/>
 <result pre="and the possibility of drug accumulation and toxicity, breastfeeding during" exact="hydroxychloroquine" post="therapy should be done with caution.53 Umifenovir (ArbidolÂ®) Umifenovir"/>
 <result pre="in administration for a few days up to one month.55" exact="Ribavirin" post="Ribavirin is a nucleoside antihepaciviral agent (anti-HCV) which has"/>
 <result pre="administration for a few days up to one month.55 Ribavirin" exact="Ribavirin" post="is a nucleoside antihepaciviral agent (anti-HCV) which has been"/>
 <result pre="antihepaciviral agent (anti-HCV) which has been suggested for COVID-19 treatment." exact="Ribavirin" post="is a direct-acting antiviral (DAA) agent.56 Ribavirin mechanism of"/>
 <result pre="for COVID-19 treatment. Ribavirin is a direct-acting antiviral (DAA) agent.56" exact="Ribavirin" post="mechanism of action in coronavirus treatment Ribavirin is a"/>
 <result pre="antiviral (DAA) agent.56 Ribavirin mechanism of action in coronavirus treatment" exact="Ribavirin" post="is a nucleoside analog that has antiviral action against"/>
 <result pre="of RNA and DNA viruses. The potential antiviral activity of" exact="ribavirin" post="is inhibition of inosine monophosphate dehydrogenase (IMPDH) cellular protein"/>
 <result pre="viral growth might be stopped. Another possible antiviral activity of" exact="ribavirin" post="is its immunomodulatory effects by suppression of IL-10.57 Ribavirin"/>
 <result pre="of ribavirin is its immunomodulatory effects by suppression of IL-10.57" exact="Ribavirin" post="also could inhibit RNA polymerase activity and therefore inhibition"/>
 <result pre="initiation and elongation, so viral protein synthesis could be inhibited." exact="Ribavirin" post="adverse reactions The most common adverse reactions of ribavirin"/>
 <result pre="inhibited. Ribavirin adverse reactions The most common adverse reactions of" exact="ribavirin" post="are CNS adverse reactions (headache, fatigue, insomnia, nervousness, etc.),"/>
 <result pre="reactions are cardiovascular events such as chest pain and flushing.52" exact="Ribavirin" post="contraindications Ribavirin is contraindicated in patients with hypersensitivity to"/>
 <result pre="cardiovascular events such as chest pain and flushing.52 Ribavirin contraindications" exact="Ribavirin" post="is contraindicated in patients with hypersensitivity to ribavirin, pregnant"/>
 <result pre="major hemoglobinopathies such as sickle cell anemia and major thalassemia.52" exact="Ribavirin" post="pharmacokinetics Ribavirin distribution could significantly prolonged in erythrocytes for"/>
 <result pre="such as sickle cell anemia and major thalassemia.52 Ribavirin pharmacokinetics" exact="Ribavirin" post="distribution could significantly prolonged in erythrocytes for about 16"/>
 <result pre="16 to 40 days, which is responsible for ribavirin-induced anemia.58" exact="Ribavirin" post="has hepatic metabolism. Its oral bioavailability (F) is about"/>
 <result pre="has hepatic metabolism. Its oral bioavailability (F) is about 64%." exact="Ribavirin" post="elimination half-life (t Â½) in the normal population is"/>
 <result pre="So because of its prolonged half-life and potential overdose toxicity," exact="ribavirin" post="is contraindicated in patients with hepatic failure (Child-Pugh class"/>
 <result pre="(Tmax) after oral administration is between 2 to 3 hours." exact="Ribavirin" post="excretion could take place through both urine and feces"/>
 <result pre="Cardiovascular diseases One of the most important side effects of" exact="ribavirin" post="is hemolytic anemia which could worsen cardiac disease in"/>
 <result pre="could induce fatal or non-fatal myocardial infarction in them. So" exact="ribavirin" post="should be avoided in patients with a history of"/>
 <result pre="a history of unstable or severe cardiac diseases. Liver diseases" exact="Ribavirin" post="is contraindicated in patients with hepatic decompensation (Child-Pugh class"/>
 <result pre="with hepatic decompensation (Child-Pugh class B and C). Kidney diseases" exact="Ribavirin" post="dosage adjustment in patients with renal failure highly depends"/>
 <result pre="if serum creatinine level rises over 2 mg/dl during administration," exact="ribavirin" post="should be discontinued promptly.27Table 3. Ribavirin dose adjustment based"/>
 <result pre="2 mg/dl during administration, ribavirin should be discontinued promptly.27Table 3." exact="Ribavirin" post="dose adjustment based on renal function. Table 3 Ribavirin"/>
 <result pre="3. Ribavirin dose adjustment based on renal function. Table 3" exact="Ribavirin" post="formulations GFR â‰¥ 50 ml/min GFR 30 to 50"/>
 <result pre="daily 200 mg once daily 1End stage renal disease Pregnancy" exact="Ribavirin" post="has teratogenic and mutagenic effects. So it is a"/>
 <result pre="drug accumulation in tissue compartments for up to 6 months," exact="ribavirin" post="administration is contraindicated in pregnant women and also in"/>
 <result pre="partner. It was suggested that pregnancy should be avoided during" exact="ribavirin" post="therapy and at least 6 months after completion of"/>
 <result pre="months after completion of therapy in women or men.53 Lactation" exact="Ribavirin" post="because of the prolonged plasma elimination half-life and molecular"/>
 <result pre="no human data available.53 Patients have undergone solid organ transplantation" exact="Ribavirin" post="may precipitate hematologic adverse effects of organ transplantation regimen"/>
 <result pre="agents (anti-HIV). Previous researches proved the in vitro efficacy of" exact="lopinavir" post="against SARS-CoV.59 Ritonavir can enhance lopinavir's elimination half-life (t"/>
 <result pre="researches proved the in vitro efficacy of lopinavir against SARS-CoV.59" exact="Ritonavir" post="can enhance lopinavir's elimination half-life (t Â½) by inhibition"/>
 <result pre="against MERS-CoV.60 Also, results revealed that lopinavir/ritonavir in combination with" exact="ribavirin" post="and IFN-Î± could promote viral clearance and enhance patientsâ€™"/>
 <result pre="clinical efficacy against COVID-19 infection. The recommended daily dose of" exact="lopinavir" post="/ritonavir is 400 and 100 mg respectively twice daily."/>
 <result pre="with the underlying disease who are infected with COVID-19.62 Also," exact="lopinavir" post="would be a promising drug of choice in children"/>
 <result pre="a critical enzyme in viral maturation and infectivity. Low dose" exact="ritonavir" post="in combination with lopinavir act as a pharmacokinetic enhancer"/>
 <result pre="viral maturation and infectivity. Low dose ritonavir in combination with" exact="lopinavir" post="act as a pharmacokinetic enhancer by inhibition of lopinavir"/>
 <result pre="with lopinavir act as a pharmacokinetic enhancer by inhibition of" exact="lopinavir" post="inactivation metabolism.63 Lopinavir/Ritonavir adverse reactions The most common adverse"/>
 <result pre="hypokalemia in patients with COVID-19 infection.64 Lopinavir/Ritonavir drug interactions Since" exact="lopinavir" post="undergoes hepatic metabolism through CYP3A4 enzyme, potential drug-drug interactions"/>
 <result pre="inhibitors or inducers of CYP3A4 enzyme and P-glycoprotein inhibitors. Also," exact="ritonavir" post="has hepatic metabolism via CYP3A4 and CYP2D6. Ritonavir has"/>
 <result pre="inhibitors. Also, ritonavir has hepatic metabolism via CYP3A4 and CYP2D6." exact="Ritonavir" post="has serious and life-threatening drug interactions with sedative-hypnotic agents,"/>
 <result pre="drugs, and ergot alkaloid agents because of the effect of" exact="ritonavir" post="on their hepatic metabolism through CYP3A4 AND CYP2D6. Concurrent"/>
 <result pre="through CYP3A4 AND CYP2D6. Concurrent use of these agents with" exact="ritonavir" post="is absolutely contraindicated and should be avoided.52 Lopinavir/Ritonavir contraindications"/>
 <result pre="with underlying kidney disease and it could be administered safely.52" exact="Ritonavir" post="also has high protein binding (about 98 to 99"/>
 <result pre="and undergo hepatic metabolism through CYP3A4 and CYP2D6. Low-dose of" exact="ritonavir" post="in combination with lopinavir as a fixed-dose agent (1:4"/>
 <result pre="through CYP3A4 and CYP2D6. Low-dose of ritonavir in combination with" exact="lopinavir" post="as a fixed-dose agent (1:4 ratio) acts as a"/>
 <result pre="(1:4 ratio) acts as a pharmacokinetic enhancer by inhibition of" exact="lopinavir" post="inactivation metabolism through inhibition of liver and intestinal CYP3A4"/>
 <result pre="liver and intestinal CYP3A4 and inhibition of P-glycoprotein efflux pump.65" exact="Ritonavir" post="could induce high serum and lymph node concentration with"/>
 <result pre="in fasting state to 4 hours in the fed state." exact="Ritonavir" post="also has small renal elimination so dosage adjustment is"/>
 <result pre="severe hepatic failure, there is no dosage adjustments available but" exact="lopinavir" post="has primary liver metabolism and its AUC will be"/>
 <result pre="and should not be stopped during pregnancy.53 Lactation Lopinavir and" exact="ritonavir" post="with a molecular weight of 629 and 721 Da"/>
 <result pre="has been suggested that during COVID-19 treatment, calcineurin inhibitors (ex." exact="cyclosporine" post="and tacrolimus) and mTOR inhibitors (ex. sirolimus and everolimus)"/>
 <result pre="calcineurin inhibitors (ex. cyclosporine and tacrolimus) and mTOR inhibitors (ex." exact="sirolimus" post="and everolimus) could be discontinued and replaced with lopinavir/ritonavir"/>
 <result pre="count and the number of cytokines such as IL-6.70 Interferon" exact="alpha" post="(IFN-Î±) IFN-Î± is a broad-spectrum antiviral agent that is"/>
 <result pre="Another concern about the administration of IFN-Î± in combination with" exact="ritonavir" post="in children is inhibition of development and growth which"/>
 <result pre="further randomized clinical trials are required to confirm its efficacy.31" exact="Azithromycin" post="Azithromycin is a macrolide antibiotic. Previous in vitro studies"/>
 <result pre="randomized clinical trials are required to confirm its efficacy.31 Azithromycin" exact="Azithromycin" post="is a macrolide antibiotic. Previous in vitro studies revealed"/>
 <result pre="antibiotic. Previous in vitro studies revealed the antiviral activity of" exact="azithromycin" post="and also it could prevent severe viral respiratory tract"/>
 <result pre="patients infected with respiratory viruses. A recent publication showed that" exact="azithromycin" post="in combination with hydroxychloroquine could have synergistic effects against"/>
 <result pre="viruses. A recent publication showed that azithromycin in combination with" exact="hydroxychloroquine" post="could have synergistic effects against COVID-19 infection. But the"/>
 <result pre="open-label non-randomized clinical trial in France revealed that co-administration of" exact="azithromycin" post="with hydroxychloroquine in COVID-19 patients was accompanied by reinforcement"/>
 <result pre="clinical trial in France revealed that co-administration of azithromycin with" exact="hydroxychloroquine" post="in COVID-19 patients was accompanied by reinforcement of the"/>
 <result pre="COVID-19 patients was accompanied by reinforcement of the effect of" exact="hydroxychloroquine" post="monotherapy, but the main limitation of this clinical trial"/>
 <result pre="data available on its efficacy against COVID-19. Remdesivir is an" exact="adenosine" post="analog with antiviral activity. A possible mechanism of antiviral"/>
 <result pre="treatment of COVID-19. A possible disadvantage of NSAIDs such as" exact="Ibuprofen" post="in COVID-19 infection is their potential effects in over-expression"/>
 <result pre="of a previous meta-analysis revealed that high dose intravenous (IV)" exact="vitamin C" post="would be a promising agent in sepsis and septic"/>
 <result pre="a life-threatening consequence of sepsis or septic shock. High dose" exact="vitamin C" post="has dual effects; it can act as a pro-oxidant"/>
 <result pre="antioxidant agent for lung epithelial cells. Another possible mechanism of" exact="vitamin C" post="is inhibition of lactate secretion from immune cells and"/>
 <result pre="of alveolar epithelial cells type II.79 So high dose IV" exact="vitamin C" post="would be a promising option in COVID-19-induced ARDS management."/>
 <result pre="promising option in COVID-19-induced ARDS management. The recommended dose of" exact="vitamin C" post="in patients with severe COVID-19 pneumonia is 50 mg/kg"/>
 <result pre="IV every 6 hours for 4 days. In this protocol," exact="hydrocortisone" post="(50 mg IV every 6 hours for 7 days)"/>
 <result pre="and safety in COVID-19 patients. Some recent studies revealed that" exact="vitamin C" post="could have a preventive role in COVID-19 lower respiratory"/>
 <result pre="respiratory tract infection. So supplementation with a moderate amount of" exact="vitamin C" post="has been suggested as a promising preventive option.80 Extracorporeal"/>
 <result pre="who develop cardiac arrhythmia and septic shock during COVID-19 pneumonia.81" exact="Deferoxamine" post="Iron toxicity has a multi-stage clinical course. First patients"/>
 <result pre="obstructive pulmonary disease, hypertension, etc.) In this group, lopinavir/ritonavir plus" exact="chloroquine" post="or hydroxychloroquine would be considered. Also according to the"/>
 <result pre="disease, hypertension, etc.) In this group, lopinavir/ritonavir plus chloroquine or" exact="hydroxychloroquine" post="would be considered. Also according to the therapeutic protocol"/>
 <result pre="48 hours. In this group, a combination of remdesivir plus" exact="chloroquine" post="or hydroxychloroquine or monotherapy of remdesivir are considered as"/>
 <result pre="In this group, a combination of remdesivir plus chloroquine or" exact="hydroxychloroquine" post="or monotherapy of remdesivir are considered as the first"/>
 <result pre="the first choice. If remdesivir is not available, lopinavir/ritonavir plus" exact="chloroquine" post="has been suggested as a second choice of therapy."/>
 <result pre="multi-organ failure. In this group, a combination of remdesivir plus" exact="chloroquine" post="or hydroxychloroquine or monotherapy of remdesivir are considered as"/>
 <result pre="In this group, a combination of remdesivir plus chloroquine or" exact="hydroxychloroquine" post="or monotherapy of remdesivir are considered as the first"/>
 <result pre="the first choice. If remdesivir is not available, lopinavir/ritonavir plus" exact="chloroquine" post="has been suggested as a second choice of therapy."/>
 <result pre="angiotensin receptor blockers (ARBs) could enhance ACE2 level. Thiazolidinediones and" exact="Ibuprofen" post="might also enhance the ACE2 level.83 So the potential"/>
 <result pre="36HamiziKAouidaneSBelaalouiGEtoposid-based therapy for severe forms of COVID-19Med Hypo2020109826 37TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res1772020104762 38ZhouDDaiSMTongQCOVID-19: a recommendation to examine the"/>
 <result pre="COVID-19Antiviral Res1772020104762 38ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020 39ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and"/>
 <result pre="hydroxychloroquine in preventing infection and progressionJ Antimicrob Chemother2020 39ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020105932"/>
 <result pre="J Antimicrob Agents2020105932 40DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
 <result pre="coronavirus: what to expect for COVID-19?Int J Antimicrob Agents2020105938 41GaoJTianZYangXBreakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends1412020727332074550 42GautretPLagierJ-CParolaPMeddebLMailheMDoudierBHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents2020105949 43SchluenzLARamos-OteroGPNawarskasJJChloroquine or" exact="hydroxychloroquine" post="for management of coronavirus disease 2019: friend or Foe?Cardiol"/>
 <result pre="of coronavirus disease 2019: friend or Foe?Cardiol Rev285202026627132769401 44HernandezAVRomanYMPasupuletiVBarbozaJJWhiteCMHydroxychloroquine or" exact="chloroquine" post="for treatment or prophylaxis of COVID-19: a living systematic"/>
 <result pre="45ChenC, PanK, WuB, LiX, ChenZ, XuQ, etÂ al. Safety of" exact="hydroxychloroquine" post="in COVID-19 and other diseases: a systematic review and"/>
 <result pre="controversial treatment for COVID-19Arch Pharmacal Res202018 47HuTYFriemanMWolframJInsights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat Nanotech1542020247249 48CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the"/>
 <result pre="Nanotech1542020247249 48CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020 49WangMCaoRZhangLYangXLiuJXuMRemdesivir and"/>
 <result pre="chloroquine for the treatment of COVID-19J Crit Care2020 49WangMCaoRZhangLYangXLiuJXuMRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="antiviral compoundsJ Clin Virol3112004697515288617 60KimUJWonE-JKeeS-JJungS-IJangH-CCase report Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntiviral Therapy21201645545926492219 61CaoBWangYWenDLiuWWangJFanGA"/>
 <result pre="COVID-19 progressionInt J Infect Dis2020 65MoltÃ³JBarbanojMJMirandaCBlancoASantosJRNegredoESimultaneous population pharmacokinetic model for" exact="lopinavir" post="and ritonavir in HIV-infected adultsClin Pharmacokinet4710200868169218783298 66PericoLBenigniARemuzziGShould COVID-19 concern"/>
 <result pre="J Infect Dis2020 65MoltÃ³JBarbanojMJMirandaCBlancoASantosJRNegredoESimultaneous population pharmacokinetic model for lopinavir and" exact="ritonavir" post="in HIV-infected adultsClin Pharmacokinet4710200868169218783298 66PericoLBenigniARemuzziGShould COVID-19 concern nephrologists? Why"/>
 <result pre="of etiology, pathogenesis, diagnosis, and ongoing clinical trialsCureus1252020 79ErolA.High-dose intravenous" exact="vitamin C" post="treatment for COVID-19. 2020. 80WangL-sWangY-rYeD-wLiuQ-qA review of the 2019"/>
</results>
